Scientific Articles

About the episodeIn this video, Prof Philip Hawkins (University College London, London, UK), addresses some important key questions surrounding amyloidosis, a…

AimsHELIOS-A was a Phase 3, open-label study of vutrisiran, an RNA interference therapeutic, in patients with hereditary transthyretin (ATTRv) amyloidosis with…

BackgroundTransthyretin cardiac amyloidosis (ATTR‐CA) is a progressive and ultimately fatal cardiomyopathy. Biomarkers reflecting multiorgan dysfunction are of…

BackgroundTafamidisexternal link, opens in a new tab was approved to treat patients with transthyretinexternal link, opens in a new tab amyloid…

Disease OverviewImmunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain…

Abstract:Transthyretincardiac amyloidosis is a rare disease that has gained significant attention in recent years because of misfolding of transthyretin fibrils…

Key PointsQuestion  Does tafamidis, 80 mg, affect cardiac function in patients with transthyretin amyloid cardiomyopathy?Findings  In this post hoc…

Amyloidoses represent a group of diseases characterized by the pathological accumulation in the extracellular area of insoluble misfolded protein material called “…

This study reports health-related quality of life (HRQL) among newly-diagnosed immunoglobulin light-chain (AL) patients (n = 914) treated with a bortezomib-based…

The American College of Cardiology (ACC) has a long history of developing documents (eg, decision pathways, health policy statements, appropriate use criteria) to…